[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

FI930058A0 - O-GLYCOLYSERAD ALFA-IFN - Google Patents

O-GLYCOLYSERAD ALFA-IFN

Info

Publication number
FI930058A0
FI930058A0 FI930058A FI930058A FI930058A0 FI 930058 A0 FI930058 A0 FI 930058A0 FI 930058 A FI930058 A FI 930058A FI 930058 A FI930058 A FI 930058A FI 930058 A0 FI930058 A0 FI 930058A0
Authority
FI
Finland
Prior art keywords
ifn
glycolyserad
alfa
glycosylated
alpha
Prior art date
Application number
FI930058A
Other languages
Finnish (fi)
Other versions
FI930058A (en
Inventor
Guenther Adolf
Adolf Himmler
Horst Johann Ahorn
Inge Kalsner
Ingrid Maurer-Fogy
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19904021917 external-priority patent/DE4021917A1/en
Priority claimed from DE19904035877 external-priority patent/DE4035877A1/en
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of FI930058A0 publication Critical patent/FI930058A0/en
Publication of FI930058A publication Critical patent/FI930058A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

The objects of the invention are O-glycosylated IFN-alpha, a process for producing the same and the use of the O-glycosylated proteins as medicinal drugs.
FI930058A 1990-07-10 1993-01-08 O-GLYCOLYSERAD ALFA-IFN FI930058A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19904021917 DE4021917A1 (en) 1990-07-10 1990-07-10 O-glycosylated alpha-interferon, used as medicament - isolated following secretion into conditioned medium of mammalian cells contg. a suitable expression plasmid
DE19904035877 DE4035877A1 (en) 1990-11-12 1990-11-12 O-glycosylated alpha interferon
PCT/EP1991/001266 WO1992001055A1 (en) 1990-07-10 1991-07-06 O-glycosylated ifn-alpha

Publications (2)

Publication Number Publication Date
FI930058A0 true FI930058A0 (en) 1993-01-08
FI930058A FI930058A (en) 1993-01-08

Family

ID=25894855

Family Applications (1)

Application Number Title Priority Date Filing Date
FI930058A FI930058A (en) 1990-07-10 1993-01-08 O-GLYCOLYSERAD ALFA-IFN

Country Status (16)

Country Link
EP (1) EP0538300B1 (en)
JP (1) JPH06502987A (en)
KR (1) KR930701601A (en)
AT (1) ATE104348T1 (en)
AU (1) AU650893B2 (en)
CA (1) CA2084514A1 (en)
CZ (1) CZ386392A3 (en)
DE (1) DE59101397D1 (en)
DK (1) DK0538300T3 (en)
ES (1) ES2063515T3 (en)
FI (1) FI930058A (en)
HU (1) HUT65846A (en)
NO (1) NO930059L (en)
PL (1) PL297610A1 (en)
SK (1) SK386392A3 (en)
WO (1) WO1992001055A1 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ245771A (en) * 1992-02-07 1994-08-26 New England Medical Center Inc Mammalian gastrin/cholecystokinin b (cck-b) receptor and antagonists
US5541071A (en) * 1992-02-07 1996-07-30 New England Medical Center Hospitals, Inc. Assay for identifying antagonists of gastrin and CCK-B receptors
EP0626448A3 (en) * 1993-05-26 1998-01-14 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Process for preparing and purifying alpha-interferon
EP0788556A1 (en) * 1994-10-28 1997-08-13 Innogenetics N.V. New polynucleic acid sequences for use in the detection and differentiation of prokaryotic organisms
WO1998006863A1 (en) * 1996-08-14 1998-02-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services A vector for polynucleotide vaccines
GB9904695D0 (en) * 1999-03-01 1999-04-21 Imp Cancer Res Tech Peptide
CA2405701A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
EP2305314B1 (en) * 2001-10-10 2015-12-23 ratiopharm GmbH Remodelling and glycoconjugation of antibodies
WO2004099231A2 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
EP1463751B1 (en) 2001-12-21 2013-05-22 Human Genome Sciences, Inc. Albumin fusion proteins
US7803777B2 (en) 2003-03-14 2010-09-28 Biogenerix Ag Branched water-soluble polymers and their conjugates
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
WO2005070138A2 (en) 2004-01-08 2005-08-04 Neose Technologies, Inc. O-linked glycosylation of peptides
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
US8268967B2 (en) 2004-09-10 2012-09-18 Novo Nordisk A/S Glycopegylated interferon α
HUE026826T2 (en) 2004-10-29 2016-07-28 Ratiopharm Gmbh Remodeling and glycopegylation of fibroblast growth factor (FGF)
EP1858543B1 (en) 2005-01-10 2013-11-27 BioGeneriX AG Glycopegylated granulocyte colony stimulating factor
WO2006121569A2 (en) 2005-04-08 2006-11-16 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US20080255026A1 (en) 2005-05-25 2008-10-16 Glycopegylated Factor 1X Glycopegylated Factor Ix
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
AR078117A1 (en) 2006-06-20 2011-10-19 Protech Pharma S A A RECOMBINANT MUTEIN OF THE GLICOSILATED HUMAN ALPHA INTERFERON, A CODIFYING GENE FOR SUCH MUTEIN, A METHOD OF PRODUCTION OF SUCH GENE, A METHOD FOR OBTAINING A EUCARIOTE CELL MANUFACTURING THIS MUTEINE, A METHOD FOR A MUTE DIFFERENT PROCEDURE
US20080280818A1 (en) 2006-07-21 2008-11-13 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
JP2010505874A (en) 2006-10-03 2010-02-25 ノヴォ ノルディスク アー／エス Purification method for polypeptide conjugates
ES2406267T3 (en) 2007-04-03 2013-06-06 Biogenerix Ag Treatment methods using glycopegylated G-CSF
MX2009013259A (en) 2007-06-12 2010-01-25 Novo Nordisk As Improved process for the production of nucleotide sugars.
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
CN103497246B (en) 2008-02-27 2016-08-10 诺沃—诺迪斯克有限公司 Conjugated factor viii molecules
EP2938726B1 (en) 2012-12-31 2017-09-27 Boehringer Ingelheim International GmbH Heterologous intron within a signal peptide
WO2014102101A1 (en) 2012-12-31 2014-07-03 Boehringer Ingelheim International Gmbh Novel intron sequences
RU2610173C1 (en) * 2016-03-30 2017-02-08 Илья Александрович Марков Recombinant plasmid pfm-ifn-17 providing expression of interferon alpha-2b of human, recombinant plasmid pfm-ap, providing expression of enzyme methionine-aminopeptidase e coli, biplasmid strain escherichia coli fm-ifn-ap (pfm-ifn-17, pfm-ap) - producer (met-) of recombinant interferon alpha -2b of human

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN150740B (en) * 1978-11-24 1982-12-04 Hoffmann La Roche
WO1983000693A1 (en) * 1981-08-14 1983-03-03 Berg, Kurt, Frimann SUBJECTS RELATING TO HUMAN INTEFERON-'alpha' SUBTYPE PROTEINS AND CORRESPONDING ANTIBODIES
DE3306060A1 (en) * 1983-02-22 1984-08-23 Boehringer Ingelheim International GmbH, 6507 Ingelheim NEW IMMUNGLOBULIN-PRODUCING HYBRID CELL LINES, THEIR USE AND METHOD FOR THE PRODUCTION THEREOF
FR2560212B1 (en) * 1984-02-24 1989-12-29 Unicet MONOCLONAL ANTIBODIES AGAINST INTERFERON A2 AND HYBRIDOMAS PRODUCING SUCH ANTIBODIES

Also Published As

Publication number Publication date
ATE104348T1 (en) 1994-04-15
KR930701601A (en) 1993-06-12
NO930059D0 (en) 1993-01-08
SK386392A3 (en) 1994-08-10
EP0538300A1 (en) 1993-04-28
EP0538300B1 (en) 1994-04-13
DE59101397D1 (en) 1994-05-19
CZ386392A3 (en) 1993-08-11
WO1992001055A1 (en) 1992-01-23
ES2063515T3 (en) 1995-01-01
JPH06502987A (en) 1994-04-07
AU8208291A (en) 1992-02-04
PL297610A1 (en) 1992-07-13
CA2084514A1 (en) 1992-01-11
NO930059L (en) 1993-01-08
DK0538300T3 (en) 1994-10-10
AU650893B2 (en) 1994-07-07
HU9300036D0 (en) 1993-04-28
FI930058A (en) 1993-01-08
HUT65846A (en) 1994-07-28

Similar Documents

Publication Publication Date Title
ATE104348T1 (en) O-GLYCOSYLATED IFN-ALPHA.
ID28003A (en) ADAMANTANA'S DEMONS
FI915826A0 (en) PHARMACEUTICAL AEMNEN.
DK1036058T3 (en) adamantane
ES2036737T3 (en) PROCEDURE FOR OBTAINING PHARMACEUTICAL MIXTURES.
DE69013684D1 (en) KNEE PROSTHESIS.
ITRM920237A1 (en) IMPROVED USE OF BRONCODILATORY MEDICINAL PRODUCTS B2.
NL8901652A (en) CARBOXAMIDE COMPOUNDS, METHODS FOR PRODUCING THE SAME AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM.
NO930226D0 (en) Cephalosporins and Homologs, Preparations and Pharmaceutical Preparations
DE58908155D1 (en) ENDOPROTHESIS OF THE HIP JOINT.
NO912825L (en) PROCEDURE FOR THE PREPARATION OF COCONJUGATE VACCINES INCLUDING IM MUNOGENT PROTEIN, HIV RELATED PEPTIDES AND ANIONIC GROUPS.
NO911429D0 (en) DRUG TREATMENT.
DE68907392D1 (en) DYSMNESIA MODIFYING MEDICINAL PRODUCTS.
NO913360L (en) PROCEDURE FOR THE PREPARATION OF SYNTHESIC GAS.
KR900007816A (en) Cyclopropyl-substituted azolylmethylcarbinol, its preparation method and its use as a medicament
NO911430D0 (en) DRUG TREATMENT.
DE59107762D1 (en) Complexes containing S (+) - phenyl-alkanoic acids and alpha-hydroxy-alkanoic acids
NO891574L (en) PROCEDURE FOR THE PREPARATION OF PHARMACEUTICAL USES.
NO892716L (en) PROCEDURE FOR PRODUCING PROTEINS.
IT9048026A0 (en) PHARMACEUTICAL AND/OR COSMETIC PREPARATION.
FR2631230B1 (en) FOLDABLE BED, ESPECIALLY FOR MEDICAL APPLICATIONS
NO891941L (en) PROCEDURE FOR THE MANUFACTURE OF CYCLOAL CADIANS.
MX9203129A (en) BMP-5 PROTEINS.
SE9002274D0 (en) NOVEL 3,3'-DITHIOBIS (PROPIONIC ESTERS).
MX9203467A (en) DERIVATIVES OF PEPTIDES.

Legal Events

Date Code Title Description
FD Application lapsed